LGVN News and Press, Longeveron Inc. From 03/31/22

Clovis Oncology (CLVS) +45% meets key goal for ovarian cancer therapy in late-stage trial. Longeveron (LGVN) +36% publishes peer reviewed study of phase 1 trial results of Lomecel-B for alzheimer’s disease in alzheimer’s & dementia: the journal of the alzheime...

Results Support Further Exploration of Therapeutic Potential of Lomecel-B to Slow Cognitive Decline, Improve Quality of Life for Alzheimer’s Patients Phase 2 Trial Recently Launched With First Patient Treated MIAMI, March 31, 2022 (GLOBE NEWSWIRE) -- Longeveron In...

Mercurity Fintech Holding (MFH) +65%. Fast Radius (FSRD) +21%. Nikola (NKLA) +18% after investor event. Femasys (FEMY) +13%. BiondVax Pharmaceuticals (BVXV) +13% on research pact to develop nanosized antibody therapies. Incannex Healthcare (IXHL) +12%. D-MARKET Elektronik&...

MIAMI, March 24, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management presented at the Second...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any of Tom’s potential 100x picks,  subscribe to his mailing list here . Source: bht2000...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any of Tom’s potential 100x picks,  subscribe to his mailing list here . VOLT Information ...

MIAMI, March 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive Offic...

Longeveron Inc. (LGVN) Q4 2021 Results Conference Call March 11, 2022 08:30 AM ET Company Participants Brendan Payne - Stern IR Geoff Green - Chief Executive Officer Dr. Joshua Hare - Co-Founder, Chief Science Officer and Chairman James Clavijo - Chief Financial Officer Presentation Operator ...

Gainers: Clearside Biomedical CLSD +38%. Cellectis (NASDAQ:CLLS) +13%. NeuroPace (NASDAQ:NPCE) +12%. 4D pharma LBPS +11%. LifeStance Health (NASDAQ:LFST) +8%. Losers: Orphazyme ORPH -37%. Aesthetic Medical International (NASDAQ:AIH) -19%. Suns...

The clinical-stage biotechnology company Longeveron (NASDAQ:LGVN) has lost ~10% in the pre-market Friday after the company signaled a potential delay for results from its Aging Frailty trial for the lead candidate, Lomecel-B. The data from the Phase 1/2 trial called “HERA...